The Impact Of Rituxan For The Treatment Of Follicular Lymphoma.
New fact-finding provides more show that treating positive lymphoma patients with an up-market drug over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly gain life span, raising questions about whether it's value taking. People with lymphoma who are in maintenance treatment "really need a analysis with their oncologist," said Dr Steven T Rosen, gaffer of the Robert H Lurie Comprehensive Cancer Center at Northwestern University in Chicago vitoviga. The memorize involved man with follicular lymphoma, one of the milder forms of non-Hodgkin lymphoma, a sitting that refers to cancers of the immune system.
Though it can be fatal, most population live for at least 10 years after diagnosis. There has been think through over whether people with the disease should take Rituxan as maintenance therapy after their original chemotherapy. In the study, which was funded in part by F Hoffmann-La Roche, a pharmaceutical assemblage that sells Rituxan, violently half of the 1019 participants took Rituxan, and the others did not klonopin prices. All beforehand had taken the drug right after receiving chemotherapy.
In the next three years, the analysis found, people taking the treat took longer, on average, to develop symptoms. Three-quarters of them made it to the three-year consequence without progression of their illness, compared with about 58 percent of those who didn't let in the drug. But the death rank over three years remained about the same, according to the report, published online Dec 21 2010 in The Lancet.
воскресенье, 14 декабря 2014 г.
вторник, 2 декабря 2014 г.
Cancer Risk From CT Scans Lower Than Previously Thought
Cancer Risk From CT Scans Lower Than Previously Thought.
The jeopardy of developing cancer as a outcome of emission exposure from CT scans may be cut than previously thought, new research suggests. That finding, scheduled to be presented Wednesday at the annual rendezvous of the Radiological Society of North America in Chicago, is based on an eight-year assay of Medicare records covering nearly 11 million patients. "What we found is that overall between two and four out of every 10000 patients who withstand a CT through are at gamble for developing secondary cancers as a result of that dispersal exposure," said Aabed Meer, an MD candidate in the sphere of influence of radiology at Stanford University in Palo Alto, Calif cytotec. "And that risk, I would say, is crop than we expected it to be," said Meer.
As a result, patients who penury a CT skim should not be fearful of the consequences, Meer stated. "If you have a stroke and requirement a CT scan of the head, the benefits of that scan at that half a mo outweigh the very minor possibility of developing a cancer as a result of the leaf through itself," he explained. "CT scans do amazing things in terms of diagnosis. Yes, there is some emanation risk virilityex.drug-purchase.info. But that grudging risk should always be put in context".
The authors set out to quantify that risk by sifting through the medical records of old patients covered by Medicare between 1998 and 2005. The researchers separated the figures into two periods: 1998 to 2001 and 2002 to 2005. In the earlier period, 42 percent of the patients had undergone CT scans. For the age 2002 to 2005, that calculate rose to 49 percent, which was not surprising given the increasing use of scans in US medical care.
Within each group, the scrutiny crew reviewed the count and type of CT scans administered to aid how many patients received low-dose diffusion (50 to 100 millisieverts) and how many got high-dose radiation (more than 100 millisieverts). They then estimated how many cancers were induced using rating cancer danger models.
The jeopardy of developing cancer as a outcome of emission exposure from CT scans may be cut than previously thought, new research suggests. That finding, scheduled to be presented Wednesday at the annual rendezvous of the Radiological Society of North America in Chicago, is based on an eight-year assay of Medicare records covering nearly 11 million patients. "What we found is that overall between two and four out of every 10000 patients who withstand a CT through are at gamble for developing secondary cancers as a result of that dispersal exposure," said Aabed Meer, an MD candidate in the sphere of influence of radiology at Stanford University in Palo Alto, Calif cytotec. "And that risk, I would say, is crop than we expected it to be," said Meer.
As a result, patients who penury a CT skim should not be fearful of the consequences, Meer stated. "If you have a stroke and requirement a CT scan of the head, the benefits of that scan at that half a mo outweigh the very minor possibility of developing a cancer as a result of the leaf through itself," he explained. "CT scans do amazing things in terms of diagnosis. Yes, there is some emanation risk virilityex.drug-purchase.info. But that grudging risk should always be put in context".
The authors set out to quantify that risk by sifting through the medical records of old patients covered by Medicare between 1998 and 2005. The researchers separated the figures into two periods: 1998 to 2001 and 2002 to 2005. In the earlier period, 42 percent of the patients had undergone CT scans. For the age 2002 to 2005, that calculate rose to 49 percent, which was not surprising given the increasing use of scans in US medical care.
Within each group, the scrutiny crew reviewed the count and type of CT scans administered to aid how many patients received low-dose diffusion (50 to 100 millisieverts) and how many got high-dose radiation (more than 100 millisieverts). They then estimated how many cancers were induced using rating cancer danger models.
Подписаться на:
Сообщения (Atom)